PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34753772-9	2022	These preclinical results reveal novel roles of tumor FGFR signaling in the regulation of cancer immunity through inhibition of the IFNgamma pathway, and the inhibitory activity of lenvatinib against FGFRs likely contributes to the enhanced antitumor activity of combination treatment comprising lenvatinib plus anti-PD-1 mAb.	lenvatinib	181-191	programmed cell death 1	Homo sapiens	317-321	
33972389-3	2021	Forty-three patients received combination therapy of programmed cell death protein 1 (PD-1) inhibitor with lenvatinib (ICI cohort 1), 108 patients received ICI-based therapy (ICI cohort 2) and 36 patients received non-ICI therapy (non-ICI cohort).	lenvatinib	107-117	programmed cell death 1	Homo sapiens	86-90	
33972389-9	2021	CONCLUSIONS: The CNVs in plasma cfDNA could predict the clinical outcome of the combination therapy of PD-1 inhibitor with lenvatinib and other ICI-based therapies in hepatobiliary cancers.	lenvatinib	123-133	programmed cell death 1	Homo sapiens	103-107	
34649778-2	2022	In this study, we aimed to investigate whether pre-treatment magnetic resonance imaging (MRI) features and MRI-based nomogram could predict the risk of disease progression of unresectable HCC after first-line lenvatinib/anti-PD-1 antibody therapy.	lenvatinib	209-219	programmed cell death 1	Homo sapiens	225-229	
35022908-1	2022	BACKGROUND: Anti-PD-1 antibodies plus lenvatinib therapeutic regimens have demonstrated a relatively high antitumor response in many solid cancers; however, the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer (GBC) has not been reported.	lenvatinib	210-220	programmed cell death 1	Homo sapiens	17-21	
34676181-1	2021	Background: Lenvatinib (LEN) combined with anti-PD-1 antibodies (PD-1) exerted promising effects on unresectable hepatocellular carcinoma (uHCC).	lenvatinib	12-22	programmed cell death 1	Homo sapiens	48-52	
34676181-1	2021	Background: Lenvatinib (LEN) combined with anti-PD-1 antibodies (PD-1) exerted promising effects on unresectable hepatocellular carcinoma (uHCC).	lenvatinib	12-22	programmed cell death 1	Homo sapiens	65-69	
34153830-10	2021	In network meta-analyses, pembrolizumab plus lenvatinib seemed the worst tolerated anti-PD-1 combination therapy.	lenvatinib	45-55	programmed cell death 1	Homo sapiens	88-92	
35611193-4	2022	CASE SUMMARY: A 39-year-old male presented with erythema, blisters and erosions on the face, neck, trunk and limbs 1 wk after receiving combination therapy with lenvatinib and toripalimab, a PD-1 inhibitor.	lenvatinib	161-171	programmed cell death 1	Homo sapiens	191-195	
33092011-2	2020	Alternatively, the potential impact of the lenvatinib in patients who showed tumor progression on PD-1/PD-L1 blockade is unknown.	lenvatinib	43-53	programmed cell death 1	Homo sapiens	98-102	
33092011-4	2020	The outcome and safety of lenvatinib administered after PD-1/PD-L1 blockade failure was analyzed retrospectively in 36 patients.	lenvatinib	26-36	programmed cell death 1	Homo sapiens	56-60	
33092011-10	2020	Lenvatinib demonstrated considerable antitumor effects with acceptable safety in patients with progressive and unresectable HCC when administered right after PD-1/PD-L1 blockade failure.	lenvatinib	0-10	programmed cell death 1	Homo sapiens	158-162	
34036623-0	2021	Lenvatinib Targets FGFR4 to Enhance Antitumor Immune Response of Anti-PD-1 in Hepatocellular Carcinoma.	lenvatinib	0-10	programmed cell death 1	Homo sapiens	70-74	
34036623-10	2021	CONCLUSIONS: Lenvatinib reduced tumor PD-L1 level and Treg differentiation to improve anti-PD-1 efficacy by blocking FGFR4.	lenvatinib	13-23	programmed cell death 1	Homo sapiens	91-95	
33496513-14	2021	CONCLUSION: Our study provided up-to-date evidence that pembrolizumab/lenvatinib combination therapy achieved objective responses in both heavily pretreated and anti-PD-1 refractory R/M HNSCC patients.	lenvatinib	70-80	programmed cell death 1	Homo sapiens	166-170	
32716739-1	2020	PURPOSE: The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC).	lenvatinib	40-50	programmed cell death 1	Homo sapiens	189-193	
32589866-2	2020	Lenvatinib, a multikinase inhibitor of VEGF receptors and other receptor tyrosine kinases, substantially decreased tumour-associated macrophages and increased infiltration of CD8 T cells, resulting in enhanced anti-tumour activity of PD-1 inhibitors in an in-vivo model.	lenvatinib	0-10	programmed cell death 1	Homo sapiens	234-238